TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med. VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Gandhi, L. AU - Garassino, M. C. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy in lung cancer JO - N Engl J Med. VL - 379 UR - https://doi.org/10.1056/NEJMc1808567 DO - 10.1056/NEJMc1808567 ID - Gandhi2018 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med. VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Mittal, D. AU - Gubin, M. M. AU - Schreiber, R. D. AU - Smyth, M. J. PY - 2014 DA - 2014// TI - New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape JO - Curr Opin Immunol VL - 27 UR - https://doi.org/10.1016/j.coi.2014.01.004 DO - 10.1016/j.coi.2014.01.004 ID - Mittal2014 ER - TY - JOUR AU - Schreiber, R. D. AU - Old, L. J. AU - Smyth, M. J. PY - 2011 DA - 2011// TI - Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion JO - Science (New York, NY). VL - 331 UR - https://doi.org/10.1126/science.1203486 DO - 10.1126/science.1203486 ID - Schreiber2011 ER - TY - JOUR AU - Cohen, J. E. AU - Merims, S. AU - Frank, S. AU - Engelstein, R. AU - Peretz, T. AU - Lotem, M. PY - 2017 DA - 2017// TI - Adoptive cell therapy: past, present and future JO - Immunotherapy. VL - 9 UR - https://doi.org/10.2217/imt-2016-0112 DO - 10.2217/imt-2016-0112 ID - Cohen2017 ER - TY - STD TI - FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome [press release]. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm574154.htm, Accessed 3 Mar 2019 2017. UR - https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm574154.htm ID - ref7 ER - TY - STD TI - FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma [press release]. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm606540.htm, Accessed 3 Mar 2019 2018. UR - https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm606540.htm ID - ref8 ER - TY - JOUR AU - Schuster, S. J. AU - Bishop, M. R. AU - Tam, C. S. AU - Waller, E. K. AU - Borchmann, P. AU - McGuirk, J. P. PY - 2019 DA - 2019// TI - Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1804980 DO - 10.1056/NEJMoa1804980 ID - Schuster2019 ER - TY - STD TI - FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma [press release]. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm581216.htm, Accessed 30 Mar 2019 2017. UR - https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm581216.htm ID - ref10 ER - TY - JOUR AU - Neelapu, S. S. AU - Locke, F. L. AU - Bartlett, N. L. AU - Lekakis, L. J. AU - Miklos, D. B. AU - Jacobson, C. A. PY - 2017 DA - 2017// TI - Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1707447 DO - 10.1056/NEJMoa1707447 ID - Neelapu2017 ER - TY - JOUR AU - Abramson, J. S. AU - Gordon, L. I. AU - Palomba, M. L. AU - Lunning, M. A. AU - Arnason, J. E. AU - Forero-Torres, A. PY - 2018 DA - 2018// TI - Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.7505 DO - 10.1200/JCO.2018.36.15_suppl.7505 ID - Abramson2018 ER - TY - JOUR AU - Locke, F. L. AU - Ghobadi, A. AU - Jacobson, C. A. AU - Miklos, D. B. AU - Lekakis, L. J. AU - Oluwole, O. O. PY - 2019 DA - 2019// TI - Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial JO - Lancet Oncol VL - 20 UR - https://doi.org/10.1016/S1470-2045(18)30864-7 DO - 10.1016/S1470-2045(18)30864-7 ID - Locke2019 ER - TY - JOUR AU - Borchmann, P. PY - 2018 DA - 2018// TI - An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) JO - HemaSphere. VL - 2 ID - Borchmann2018 ER - TY - JOUR AU - Hopfinger, G. AU - Jäger, U. AU - Worel, N. PY - 2019 DA - 2019// TI - CAR-T Cell Therapy in diffuse large B cell lymphoma: hype and hope JO - HemaSphere. VL - 3 UR - https://doi.org/10.1097/HS9.0000000000000185 DO - 10.1097/HS9.0000000000000185 ID - Hopfinger2019 ER - TY - JOUR AU - Santomasso, B. D. AU - Park, J. H. AU - Salloum, D. AU - Riviere, I. AU - Flynn, J. AU - Mead, E. PY - 2018 DA - 2018// TI - Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-17-1319 DO - 10.1158/2159-8290.CD-17-1319 ID - Santomasso2018 ER - TY - JOUR AU - Liu, H. AU - Horan, L. H. AU - Grupp, S. A. AU - Barrett, D. M. AU - Liu, C. PY - 2018 DA - 2018// TI - Abstract 1537: Anti-CD19 ARTEMIS™ T cells prevent excessive inflammatory cytokine release, including IL-6, in a co-culture model of CRS JO - Cancer Res VL - 78 ID - Liu2018 ER - TY - JOUR AU - Ying, Z. T. AU - Long, L. AU - Liu, H. AU - Zhang, M. AU - He, P. AU - Rizzieri, D. PY - 2018 DA - 2018// TI - ET190L1-ARTEMIS T cell therapy to induce complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.3049 DO - 10.1200/JCO.2018.36.15_suppl.3049 ID - Ying2018 ER - TY - JOUR AU - Ying, Z. AU - Long, L. AU - Liu, H. AU - Song, Y. AU - Rizzieri, D. A. AU - Nejadnik, B. PY - 2018 DA - 2018// TI - ET190L1-Artemis T cell therapy results in durable disease remissions with no cytokine release syndrome or neurotoxicity in patients with relapsed and refractory B-cell lymphoma JO - Blood. VL - 132 ID - Ying2018 ER - TY - JOUR AU - Shalabi, H. AU - Kraft, I. L. AU - Wang, H. W. AU - Yuan, C. M. AU - Yates, B. AU - Delbrook, C. PY - 2018 DA - 2018// TI - Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma JO - Haematologica. VL - 103 UR - https://doi.org/10.3324/haematol.2017.183459 DO - 10.3324/haematol.2017.183459 ID - Shalabi2018 ER - TY - JOUR AU - Fry, T. J. AU - Shah, N. N. AU - Orentas, R. J. AU - Stetler-Stevenson, M. AU - Yuan, C. M. AU - Ramakrishna, S. PY - 2017 DA - 2017// TI - CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy JO - Nat Med VL - 24 UR - https://doi.org/10.1038/nm.4441 DO - 10.1038/nm.4441 ID - Fry2017 ER - TY - JOUR AU - Sotillo, E. AU - Barrett, D. M. AU - Black, K. L. AU - Bagashev, A. AU - Oldridge, D. AU - Wu, G. PY - 2015 DA - 2015// TI - Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy JO - Cancer Discov. VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-1020 DO - 10.1158/2159-8290.CD-15-1020 ID - Sotillo2015 ER - TY - JOUR AU - Hossain, N. AU - Sahaf, B. AU - Abramian, M. AU - Spiegel, J. Y. AU - Kong, K. AU - Kim, S. PY - 2018 DA - 2018// TI - Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies JO - Blood. VL - 132 ID - Hossain2018 ER - TY - JOUR AU - Shah, N. N. AU - Zhu, F. AU - Taylor, C. AU - Schneider, D. AU - Krueger, W. AU - Worden, A. PY - 2018 DA - 2018// TI - A phase 1 study with point-of-care manufacturing of dual targeted, tandem anti-CD19, anti-CD20 chimeric antigen receptor modified T (CAR-T) cells for relapsed, refractory, non-Hodgkin lymphoma JO - Blood. VL - 132 ID - Shah2018 ER - TY - JOUR AU - Ardeshna, K. AU - Marzolini, M. A. V. AU - Osborne, W. AU - Al-Hajj, M. AU - Thomas, S. AU - Faulkner, J. PY - 2018 DA - 2018// TI - Study of AUTO3, the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22, followed by anti-PD1 consolidation in patients with relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL): Alexander Study JO - Blood. VL - 132 ID - Ardeshna2018 ER - TY - JOUR AU - Park, J. H. AU - Palomba, M. L. AU - Batlevi, C. L. AU - Riviere, I. AU - Wang, X. AU - Senechal, B. PY - 2018 DA - 2018// TI - A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL “armored” CAR T cells in patients with relapsed or refractory NHL and CLL including Richter’s transformation JO - Blood. VL - 132 ID - Park2018 ER - TY - JOUR AU - Akard, L. P. AU - Jaglowski, S. AU - Devine, S. M. AU - McKinney, M. S. AU - Vasconcelles, M. AU - Huet, H. PY - 2017 DA - 2017// TI - ACTR087, autologous T lymphocytes expressing antibody coupled T-cell receptors (ACTR), induces complete responses in patients with relapsed or refractory CD20-positive B-cell lymphoma, in combination with rituximab JO - Blood. VL - 130 ID - Akard2017 ER - TY - JOUR AU - Flinn, I. W. AU - Cohen, J. B. AU - Akard, L. P. AU - Jaglowski, S. AU - Vasconcelles, M. AU - Ranger, A. PY - 2018 DA - 2018// TI - Preliminary clinical results of a phase 1 study evaluating the safety and anti-tumor activity of ACTR707 in combination with rituximab in subjects with relapsed or refractory CD20+ B-cell lymphoma JO - Blood. VL - 132 ID - Flinn2018 ER - TY - JOUR AU - Zhao, Z. AU - Condomines, M. AU - Stegen, S. J. C. AU - Perna, F. AU - Kloss, C. C. AU - Gunset, G. PY - 2015 DA - 2015// TI - Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells JO - Cancer Cell VL - 28 UR - https://doi.org/10.1016/j.ccell.2015.09.004 DO - 10.1016/j.ccell.2015.09.004 ID - Zhao2015 ER - TY - JOUR AU - Grupp, S. A. AU - Maude, S. L. AU - Shaw, P. A. AU - Aplenc, R. AU - Barrett, D. M. AU - Callahan, C. PY - 2015 DA - 2015// TI - Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019) JO - Blood. VL - 126 ID - Grupp2015 ER - TY - JOUR AU - Huet, H. A. AU - Judge, C. AU - Barnitz, R. A. AU - Boomer, R. AU - McGinness, K. AU - Shin, J. PY - 2016 DA - 2016// TI - Targeting CD20+ Relapsed refractory B cell lymphoma with ACTR087, antibody-coupled T-cell receptor (ACTR) engineered autologous T cells, in combination with rituximab JO - Blood. VL - 128 ID - Huet2016 ER - TY - JOUR AU - Kudo, K. AU - Imai, C. AU - Lorenzini, P. AU - Kamiya, T. AU - Kono, K. AU - Davidoff, A. M. PY - 2014 DA - 2014// TI - T Lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-1365 DO - 10.1158/0008-5472.CAN-13-1365 ID - Kudo2014 ER - TY - JOUR AU - Goebeler, M. -. E. AU - Knop, S. AU - Viardot, A. AU - Kufer, P. AU - Topp, M. S. AU - Einsele, H. PY - 2016 DA - 2016// TI - Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2014.59.1586 DO - 10.1200/JCO.2014.59.1586 ID - Goebeler2016 ER - TY - JOUR AU - Viardot, A. AU - Goebeler, M. E. AU - Hess, G. AU - Neumann, S. AU - Pfreundschuh, M. AU - Adrian, N. PY - 2016 DA - 2016// TI - Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2015-06-651380 DO - 10.1182/blood-2015-06-651380 ID - Viardot2016 ER - TY - JOUR AU - Hutchings, M. AU - Iacoboni, G. AU - Morschhauser, F. AU - Offner, F. AU - Sureda, A. AU - Salles, G. A. PY - 2018 DA - 2018// TI - CD20-Tcb (RG6026), a novel “2:1” format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin’s lymphoma: preliminary results from a phase I first in human trial JO - Blood. VL - 132 ID - Hutchings2018 ER - TY - JOUR AU - Budde, L. E. AU - Sehn, L. H. AU - Assouline, S. AU - Flinn, I. W. AU - Isufi, I. AU - Yoon, S. -. S. PY - 2018 DA - 2018// TI - Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study JO - Blood. VL - 132 ID - Budde2018 ER - TY - JOUR AU - Caimi, P. AU - Kahl, B. S. AU - Hamadani, M. AU - Carlo-Stella, C. AU - He, S. AU - Ungar, D. PY - 2018 DA - 2018// TI - Safety and efficacy of Adct-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma: interim results from the phase 1 first-in-human study JO - Blood. VL - 132 ID - Caimi2018 ER - TY - JOUR AU - Collins, G. P. AU - Horwitz, S. M. AU - Davies, A. AU - Karnad, A. AU - Samaniego, F. AU - Spira, A. I. PY - 2018 DA - 2018// TI - Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based CD25-targeting antibody drug conjugate, in a phase 1 study of relapsed/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma JO - Blood. VL - 132 ID - Collins2018 ER - TY - JOUR AU - Hamadani, M. AU - Collins, G. P. AU - Samaniego, F. AU - Spira, A. I. AU - Davies, A. AU - Radford, J. PY - 2018 DA - 2018// TI - Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma JO - Blood. VL - 132 ID - Hamadani2018 ER - TY - JOUR AU - Fanale, M. A. AU - Hamlin, P. A. AU - Park, S. I. AU - Persky, D. O. AU - Higgins, J. P. AU - Burnett, C. PY - 2018 DA - 2018// TI - Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.7580 DO - 10.1200/JCO.2018.36.15_suppl.7580 ID - Fanale2018 ER - TY - JOUR AU - Advani, R. AU - Flinn, I. AU - Popplewell, L. AU - Forero, A. AU - Bartlett, N. L. AU - Ghosh, N. PY - 2018 DA - 2018// TI - CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1807315 DO - 10.1056/NEJMoa1807315 ID - Advani2018 ER - TY - JOUR AU - Herrera, A. F. AU - Patel, M. R. AU - Burke, J. M. AU - Advani, R. H. AU - Cheson, B. D. AU - Sharman, J. P. PY - 2017 DA - 2017// TI - A phase I study of the anti-CD79b THIOMAB-drug conjugate DCDS0780A in patients (pts) with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL) JO - Blood. VL - 130 ID - Herrera2017 ER - TY - JOUR AU - Kolstad, A. AU - Madsbu, U. AU - Beasley, M. AU - Bayne, M. AU - Illidge, T. M. AU - O’Rourke, N. PY - 2017 DA - 2017// TI - 177 Lu-lilotomab satetraxetan, a novel CD37-targeted antibody-radionuclide conjugate in relapsed non-Hodgkin’s lymphoma (NHL): updated results of an ongoing phase I/II study (LYMRIT 37-01) JO - Blood. VL - 130 ID - Kolstad2017 ER - TY - JOUR AU - Mossner, E. AU - Brunker, P. AU - Moser, S. AU - Puntener, U. AU - Schmidt, C. AU - Herter, S. PY - 2010 DA - 2010// TI - Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity JO - Blood. VL - 115 UR - https://doi.org/10.1182/blood-2009-06-225979 DO - 10.1182/blood-2009-06-225979 ID - Mossner2010 ER - TY - JOUR AU - Nagorsen, D. AU - Kufer, P. AU - Baeuerle, P. A. AU - Bargou, R. PY - 2012 DA - 2012// TI - Blinatumomab: a historical perspective JO - Pharmacol Ther VL - 136 UR - https://doi.org/10.1016/j.pharmthera.2012.07.013 DO - 10.1016/j.pharmthera.2012.07.013 ID - Nagorsen2012 ER - TY - JOUR AU - Nagorsen, D. AU - Baeuerle, P. A. PY - 2011 DA - 2011// TI - Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab JO - Exp Cell Res VL - 317 UR - https://doi.org/10.1016/j.yexcr.2011.03.010 DO - 10.1016/j.yexcr.2011.03.010 ID - Nagorsen2011 ER - TY - JOUR AU - Haas, C. AU - Krinner, E. AU - Brischwein, K. AU - Hoffmann, P. AU - Lutterbuse, R. AU - Schlereth, B. PY - 2009 DA - 2009// TI - Mode of cytotoxic action of T cell-engaging BiTE antibody MT110 JO - Immunobiology. VL - 214 UR - https://doi.org/10.1016/j.imbio.2008.11.014 DO - 10.1016/j.imbio.2008.11.014 ID - Haas2009 ER - TY - JOUR AU - Löffler, A. AU - Kufer, P. AU - Lutterbüse, R. AU - Zettl, F. AU - Daniel, P. T. AU - Schwenkenbecher, J. M. PY - 2000 DA - 2000// TI - A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes JO - Blood. VL - 95 ID - Löffler2000 ER - TY - JOUR AU - Schlereth, B. AU - Quadt, C. AU - Dreier, T. AU - Kufer, P. AU - Lorenczewski, G. AU - Prang, N. PY - 2006 DA - 2006// TI - T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct JO - Cancer Immunol Immunother VL - 55 UR - https://doi.org/10.1007/s00262-005-0001-1 DO - 10.1007/s00262-005-0001-1 ID - Schlereth2006 ER - TY - JOUR AU - Bacac, M. AU - Fauti, T. AU - Sam, J. AU - Colombetti, S. AU - Weinzierl, T. AU - Ouaret, D. PY - 2016 DA - 2016// TI - A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1696 DO - 10.1158/1078-0432.CCR-15-1696 ID - Bacac2016 ER - TY - JOUR AU - Bacac, M. AU - Klein, C. AU - Umana, P. PY - 2016 DA - 2016// TI - CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors JO - Oncoimmunology. VL - 5 UR - https://doi.org/10.1080/2162402X.2016.1203498 DO - 10.1080/2162402X.2016.1203498 ID - Bacac2016 ER - TY - JOUR AU - Bacac, M. AU - Colombetti, S. AU - Herter, S. AU - Sam, J. AU - Perro, M. AU - Chen, S. PY - 2018 DA - 2018// TI - CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-18-0455 DO - 10.1158/1078-0432.CCR-18-0455 ID - Bacac2018 ER - TY - JOUR AU - Sun, L. L. AU - Ellerman, D. AU - Mathieu, M. AU - Hristopoulos, M. AU - Chen, X. AU - Li, Y. PY - 2015 DA - 2015// TI - Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies JO - Sci Transl Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aaa4802 DO - 10.1126/scitranslmed.aaa4802 ID - Sun2015 ER - TY - JOUR AU - Zammarchi, F. r. a. n. c. e. s. c. a. AU - Corbett, S. i. m. o. n. AU - Adams, L. a. u. r. e. n. AU - Tyrer, P. e. t. e. r. C. AU - Kiakos, K. o. n. s. t. a. n. t. i. n. o. s. AU - Janghra, N. a. r. i. n. d. e. r. AU - Marafioti, T. e. r. e. s. a. AU - Britten, C. h. a. r. l. e. s. E. AU - Havenith, C. a. r. i. n. E. G. AU - Chivers, S. i. m. o. n. AU - D’Hooge, F. r. a. n. c. o. i. s. AU - Williams, D. a. v. i. d. G. AU - Tiberghien, A. r. n. a. u. d. AU - Howard, P. h. i. l. i. p. W. AU - Hartley, J. o. h. n. A. AU - van Berkel, P. a. t. r. i. c. k. H. PY - 2018 DA - 2018// TI - ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2017-10-813493 DO - 10.1182/blood-2017-10-813493 ID - Zammarchi2018 ER - TY - JOUR AU - Radford, J. AU - Kahl, B. S. AU - Hamadani, M. AU - Carlo-Stella, C. AU - Caimi, P. AU - Ardeshna, K. M. PY - 2018 DA - 2018// TI - Interim results from the first-in-human clinical trial of Adct-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory diffuse large B-cell lymphoma JO - Blood. VL - 132 ID - Radford2018 ER - TY - JOUR AU - Strauchen, J. A. AU - Breakstone, B. A. PY - 1987 DA - 1987// TI - IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases JO - Am J Pathol VL - 126 ID - Strauchen1987 ER - TY - JOUR AU - Flynn, M. J. AU - Zammarchi, F. AU - Tyrer, P. C. AU - Akarca, A. U. AU - Janghra, N. AU - Britten, C. E. PY - 2016 DA - 2016// TI - ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies JO - Mol Cancer Ther VL - 15 UR - https://doi.org/10.1158/1535-7163.MCT-16-0233 DO - 10.1158/1535-7163.MCT-16-0233 ID - Flynn2016 ER - TY - JOUR AU - Willert, E. K. AU - Robinson, G. L. AU - Rajagopalan, S. AU - Brieschke, B. AU - Erdman, J. AU - Neill, J. PY - 2015 DA - 2015// TI - Abstract 2477: Engineered toxin bodies: a next-generation immunotoxin scaffold with novel immuno-oncology functionality JO - Cancer Res VL - 75 ID - Willert2015 ER - TY - JOUR AU - Chao, M. P. AU - Alizadeh, A. A. AU - Tang, C. AU - Myklebust, J. H. AU - Varghese, B. AU - Gill, S. PY - 2010 DA - 2010// TI - Anti-CD47 Antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma JO - Cell. VL - 142 UR - https://doi.org/10.1016/j.cell.2010.07.044 DO - 10.1016/j.cell.2010.07.044 ID - Chao2010 ER - TY - JOUR AU - Liu, J. i. e. AU - Wang, L. i. j. u. a. n. AU - Zhao, F. e. i. f. e. i. AU - Tseng, S. e. r. e. n. a. AU - Narayanan, C. y. n. d. h. a. v. i. AU - Shura, L. e. i. AU - Willingham, S. t. e. p. h. e. n. AU - Howard, M. a. u. r. e. e. n. AU - Prohaska, S. u. s. a. n. AU - Volkmer, J. e. n. s. AU - Chao, M. a. r. k. AU - Weissman, I. r. v. i. n. g. L. AU - Majeti, R. a. v. i. n. d. r. a. PY - 2015 DA - 2015// TI - Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential JO - PLOS ONE VL - 10 UR - https://doi.org/10.1371/journal.pone.0137345 DO - 10.1371/journal.pone.0137345 ID - Liu2015 ER - TY - JOUR AU - Sharma, P. AU - Allison, J. P. PY - 2015 DA - 2015// TI - The future of immune checkpoint therapy JO - Science. VL - 348 UR - https://doi.org/10.1126/science.aaa8172 DO - 10.1126/science.aaa8172 ID - Sharma2015 ER - TY - JOUR AU - Keir, M. E. AU - Butte, M. J. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2008 DA - 2008// TI - PD-1 and its ligands in tolerance and immunity JO - Annu Rev Immunol. VL - 26 UR - https://doi.org/10.1146/annurev.immunol.26.021607.090331 DO - 10.1146/annurev.immunol.26.021607.090331 ID - Keir2008 ER - TY - JOUR AU - Green, M. R. AU - Monti, S. AU - Rodig, S. J. AU - Juszczynski, P. AU - Currie, T. AU - O’Donnell, E. PY - 2010 DA - 2010// TI - Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma JO - Blood. VL - 116 UR - https://doi.org/10.1182/blood-2010-05-282780 DO - 10.1182/blood-2010-05-282780 ID - Green2010 ER - TY - JOUR AU - Roemer, M. G. AU - Advani, R. H. AU - Ligon, A. H. AU - Natkunam, Y. AU - Redd, R. A. AU - Homer, H. PY - 2016 DA - 2016// TI - PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.66.4482 DO - 10.1200/JCO.2016.66.4482 ID - Roemer2016 ER - TY - JOUR AU - Armand, P. AU - Engert, A. AU - Younes, A. AU - Fanale, M. AU - Santoro, A. AU - Zinzani, P. L. PY - 2018 DA - 2018// TI - Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.76.0793 DO - 10.1200/JCO.2017.76.0793 ID - Armand2018 ER - TY - JOUR AU - Chen, R. AU - Zinzani, P. L. AU - Fanale, M. A. AU - Armand, P. AU - Johnson, N. A. AU - Brice, P. PY - 2017 DA - 2017// TI - Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.72.1316 DO - 10.1200/JCO.2016.72.1316 ID - Chen2017 ER - TY - JOUR AU - Ansell, S. AU - Gutierrez, M. E. AU - Shipp, M. A. AU - Gladstone, D. AU - Moskowitz, A. AU - Borello, I. PY - 2016 DA - 2016// TI - A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039) JO - Blood. VL - 128 ID - Ansell2016 ER - TY - JOUR AU - Herrera, A. F. AU - Moskowitz, A. J. AU - Bartlett, N. L. AU - Vose, J. M. AU - Ramchandren, R. AU - Feldman, T. A. PY - 2018 DA - 2018// TI - Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-10-811224 DO - 10.1182/blood-2017-10-811224 ID - Herrera2018 ER - TY - JOUR AU - Ramchandren, R. AU - Fanale, M. A. AU - Rueda, A. AU - Armand, P. AU - Trněný, M. AU - Feldman, T. A. PY - 2017 DA - 2017// TI - Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 Study JO - Blood. VL - 130 ID - Ramchandren2017 ER - TY - JOUR AU - Chapuy, B. AU - Roemer, M. G. AU - Stewart, C. AU - Tan, Y. AU - Abo, R. P. AU - Zhang, L. PY - 2016 DA - 2016// TI - Targetable genetic features of primary testicular and primary central nervous system lymphomas JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2015-10-673236 DO - 10.1182/blood-2015-10-673236 ID - Chapuy2016 ER - TY - JOUR AU - Zinzani, P. L. AU - Ribrag, V. AU - Moskowitz, C. H. AU - Michot, J. M. AU - Kuruvilla, J. AU - Balakumaran, A. PY - 2017 DA - 2017// TI - Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma JO - Blood. VL - 130 UR - https://doi.org/10.1182/blood-2016-12-758383 DO - 10.1182/blood-2016-12-758383 ID - Zinzani2017 ER - TY - JOUR AU - Nayak, L. AU - Iwamoto, F. M. AU - LaCasce, A. AU - Mukundan, S. AU - Roemer, M. G. M. AU - Chapuy, B. PY - 2017 DA - 2017// TI - PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2017-01-764209 DO - 10.1182/blood-2017-01-764209 ID - Nayak2017 ER - TY - JOUR AU - Chen, B. J. AU - Chapuy, B. AU - Ouyang, J. AU - Sun, H. H. AU - Roemer, M. G. AU - Xu, M. L. PY - 2013 DA - 2013// TI - PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0855 DO - 10.1158/1078-0432.CCR-13-0855 ID - Chen2013 ER - TY - JOUR AU - Roosbroeck, K. AU - Ferreiro, J. F. AU - Tousseyn, T. AU - Krogt, J. A. AU - Michaux, L. AU - Pienkowska-Grela, B. PY - 2016 DA - 2016// TI - Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies JO - Genes Chromosomes Cancer VL - 55 UR - https://doi.org/10.1002/gcc.22345 DO - 10.1002/gcc.22345 ID - Roosbroeck2016 ER - TY - JOUR AU - Lesokhin, A. M. AU - Ansell, S. M. AU - Armand, P. AU - Scott, E. C. AU - Halwani, A. AU - Gutierrez, M. PY - 2016 DA - 2016// TI - Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.65.9789 DO - 10.1200/JCO.2015.65.9789 ID - Lesokhin2016 ER - TY - JOUR AU - Andorsky, D. J. AU - Yamada, R. E. AU - Said, J. AU - Pinkus, G. S. AU - Betting, D. J. AU - Timmerman, J. M. PY - 2011 DA - 2011// TI - Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-2660 DO - 10.1158/1078-0432.CCR-10-2660 ID - Andorsky2011 ER - TY - JOUR AU - Smeltzer, J. P. AU - Jones, J. M. AU - Ziesmer, S. C. AU - Grote, D. M. AU - Xiu, B. AU - Ristow, K. M. PY - 2014 DA - 2014// TI - Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2367 DO - 10.1158/1078-0432.CCR-13-2367 ID - Smeltzer2014 ER - TY - JOUR AU - Yang, Z. Z. AU - Grote, D. M. AU - Ziesmer, S. C. AU - Xiu, B. AU - Novak, A. J. AU - Ansell, S. M. PY - 2015 DA - 2015// TI - PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival JO - Blood Cancer J VL - 5 UR - https://doi.org/10.1038/bcj.2015.1 DO - 10.1038/bcj.2015.1 ID - Yang2015 ER - TY - JOUR AU - Palomba, M. L. AU - Till, B. G. AU - Park, S. I. AU - Morschhauser, F. AU - Cartron, G. AU - Marks, R. PY - 2017 DA - 2017// TI - A phase Ib study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) JO - Hematol Oncol VL - 35 UR - https://doi.org/10.1002/hon.2437_126 DO - 10.1002/hon.2437_126 ID - Palomba2017 ER - TY - JOUR AU - Jurczak, W. AU - Rule, S. AU - Townsend, W. AU - Tucker, D. AU - Sarholz, B. AU - Scheele, J. PY - 2018 DA - 2018// TI - A phase I/II, first in human trial of the Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies JO - Blood. VL - 132 ID - Jurczak2018 ER - TY - JOUR AU - Soumerai, J. D. AU - Pagel, J. M. AU - Jagadeesh, D. AU - Salman, H. S. AU - Kenkre, V. P. AU - Asch, A. S. PY - 2018 DA - 2018// TI - Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.7519 DO - 10.1200/JCO.2018.36.15_suppl.7519 ID - Soumerai2018 ER - TY - JOUR AU - Harb, W. A. AU - Diefenbach, C. S. AU - Lakhani, N. AU - Rutherford, S. C. AU - Schreeder, M. T. AU - Ansell, S. M. PY - 2017 DA - 2017// TI - Phase 1 clinical safety, pharmacokinetics (PK), and activity of apilimod dimesylate (LAM-002A), a first-in-class inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), in patients with relapsed or refractory B-cell malignancies JO - Blood. VL - 130 ID - Harb2017 ER - TY - JOUR AU - Forero-Torres, A. AU - Rosen, S. AU - Smith, D. C. AU - Lesser, G. AU - Peguero, J. AU - Gupta, S. PY - 2017 DA - 2017// TI - Preliminary results from an ongoing phase 1/2 study of INCB057643, a bromodomain and extraterminal (BET) protein inhibitor, in patients (pts) with advanced malignancies JO - Blood. VL - 130 ID - Forero-Torres2017 ER - TY - JOUR AU - Querfeld, C. AU - Foss, F. M. AU - Kim, Y. H. AU - Pinter-Brown, L. AU - William, B. M. AU - Porcu, P. PY - 2018 DA - 2018// TI - Phase 1 trial of cobomarsen, an inhibitor of Mir-155, in cutaneous T cell lymphoma JO - Blood. VL - 132 ID - Querfeld2018 ER - TY - JOUR AU - Maruyama, D. AU - Tobinai, K. AU - Makita, S. AU - Ishida, T. AU - Kusumoto, S. AU - Ishitsuka, K. PY - 2017 DA - 2017// TI - First-in-human study of the EZH1/2 dual inhibitor DS-3201b in patients with relapsed or refractory non-Hodgkin lymphomas — preliminary results JO - Blood. VL - 130 ID - Maruyama2017 ER - TY - JOUR AU - Li, L. AU - Xiao, S. AU - Young, K. H. AU - Zhang, L. AU - Li, X. AU - Fu, X. PY - 2017 DA - 2017// TI - Efficacy and safety of novel targeted drug’ apatinib in relapse or refractory non-Hodgkin lymphoma: an open label, single-armed, exploratory study JO - Blood. VL - 130 ID - Li2017 ER - TY - JOUR AU - Goodstal, S. M. AU - Ma, J. AU - Lin, J. AU - Crandall, T. AU - Crowley, L. AU - Bender, A. PY - 2017 DA - 2017// TI - M7583 is a highly selective and potent second generation BTK inhibitor for treatment of B-cell malignancies JO - Blood. VL - 130 ID - Goodstal2017 ER - TY - JOUR AU - Zelenetz, A. D. AU - Soumerai, J. D. AU - Jagadeesh, D. AU - Reddy, N. AU - Stathis, A. AU - Asch, A. S. PY - 2018 DA - 2018// TI - Preliminary safety and efficacy results with an intermittent schedule of the PI3kδ inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies JO - Blood. VL - 132 ID - Zelenetz2018 ER - TY - JOUR AU - Gayle, S. AU - Landrette, S. AU - Beeharry, N. AU - Conrad, C. AU - Hernandez, M. AU - Beckett, P. PY - 2017 DA - 2017// TI - Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma JO - Blood. VL - 129 UR - https://doi.org/10.1182/blood-2016-09-736892 DO - 10.1182/blood-2016-09-736892 ID - Gayle2017 ER -